Private Capital Advisors Inc. Purchases New Holdings in Immunome, Inc. (NASDAQ:IMNM)

Private Capital Advisors Inc. purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 38,501 shares of the company's stock, valued at approximately $259,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Enavate Sciences GP LLC acquired a new stake in shares of Immunome in the fourth quarter valued at about $36,939,000. JPMorgan Chase & Co. increased its position in shares of Immunome by 2,540.4% in the fourth quarter. JPMorgan Chase & Co. now owns 648,610 shares of the company's stock valued at $6,888,000 after acquiring an additional 624,045 shares during the last quarter. Granahan Investment Management LLC acquired a new stake in shares of Immunome in the fourth quarter valued at about $3,337,000. Renaissance Technologies LLC increased its position in shares of Immunome by 2,696.5% in the fourth quarter. Renaissance Technologies LLC now owns 316,000 shares of the company's stock valued at $3,356,000 after acquiring an additional 304,700 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in shares of Immunome by 127.3% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 500,000 shares of the company's stock valued at $5,310,000 after acquiring an additional 280,000 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Trading Up 8.1%

Shares of NASDAQ:IMNM traded up $0.78 during trading on Thursday, reaching $10.45. 1,250,355 shares of the stock were exchanged, compared to its average volume of 910,264. Immunome, Inc. has a 12 month low of $5.15 and a 12 month high of $16.81. The firm has a market cap of $909.25 million, a PE ratio of -3.29 and a beta of 1.92. The stock has a 50-day moving average price of $8.77 and a 200-day moving average price of $8.89.

Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.66) by $0.14. Immunome had a negative return on equity of 71.65% and a negative net margin of 1,875.21%. The company had revenue of $2.93 million during the quarter, compared to analysts' expectations of $0.46 million. On average, sell-side analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wedbush reaffirmed an "outperform" rating and issued a $21.00 target price (down previously from $33.00) on shares of Immunome in a research report on Tuesday, May 13th. Wall Street Zen raised Immunome from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Lake Street Capital assumed coverage on Immunome in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 target price on the stock. Stephens reissued an "overweight" rating and set a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Finally, Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $23.33.

Insider Activity

In other news, Director Jean Jacques Bienaime acquired 5,000 shares of Immunome stock in a transaction dated Tuesday, June 3rd. The stock was bought at an average price of $9.38 per share, for a total transaction of $46,900.00. Following the completion of the acquisition, the director directly owned 36,415 shares in the company, valued at approximately $341,572.70. The trade was a 15.92% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.